The 75% CIDP responder rate and streamlined trial design significantly de-risk the CAPTIVATE program and support accelerated path to Part B top-line data by YE'26. With ~$1.2B cash runway into 2030 and multiple catalysts across gMG, CIDP, MMN, and DNTH212 over the next 6-18 months, the risk/reward is skewed positively. Monitor Ph. 3 gMG EMERGE initiation in mid-2026 and Ph. 2 MMN data in Q4'26 as the next key value inflection points.
Price Chart
Executive Summary
Dianthus Therapeutics posted an updated corporate presentation disclosing a 75% confirmed responder rate from the first 40 patients completing Part A of the Phase 3 CAPTIVATE trial of claseprubart in CIDP. The data supports an early GO decision and a streamlined trial design with ~1/3 fewer Part B patients, with Part B top-line guidance expected by YE'26. The filing also reiterates upcoming catalysts: Ph. 3 gMG EMERGE initiation (mid-'26), Ph. 2 MMN MoMeNtum data (Q4'26), and Ph. 1 DNTH212 data (2H'26).
Key Facts
- 75% confirmed responder rate (30 of 40) in Part A of CAPTIVATE Ph. 3 CIDP trial, exceeding the 50% threshold for GO decision
- CAPTIVATE trial design streamlined: Part B reduced from 192 to 128 patients, Part A enrollment capped at 256 vs. 480
- No related serious infections, no clinical symptoms of DIL, no related SAEs or discontinuations in interim analysis
- Cash position of ~$1.2B as of March 31, 2026, with runway into 2030
- FDA Orphan Drug Designation received May 2026 for claseprubart in Myasthenia Gravis
- Ph. 3 gMG EMERGE trial initiation expected mid-2026 with top-line data 2H'28
- Ph. 2 MMN MoMeNtum top-line data expected Q4'26
- Ph. 1 DNTH212 healthy volunteer top-line data expected 2H'26
Financial Impact
No financial figures reported in filing; cash position of ~$1.2B disclosed as of March 31, 2026
Risk Factors
- Interim analysis based on only 40 patients — final Part A and Part B results may differ
- Ph. 3 gMG EMERGE top-line data not expected until 2H'28, a long wait for pivotal readout
- Competitive landscape includes approved C5 inhibitors (Soliris, Ultomiris), FcRn blockers (Vyvgart), and emerging aC1s competitors (riliprubart, empasiprubart)
- ANA positivity observed in 36.4% of 600mg/4mL arm in Ph. 2 gMG, though no clinical DIL symptoms reported
- All pipeline candidates are investigational — no approved products or revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001690585-26-000029 |
| Document: dnth-20260612.htm | 0001690585-26-000029 |
| Document: 0001690585-26-000029-index-headers.html | 0001690585-26-000029 |
| Document: 0001690585-26-000029-index.html | 0001690585-26-000029 |
| Document: 0001690585-26-000029.txt | 0001690585-26-000029 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | Insider Cluster | $112.41 $103.28 | ▼ −8.12% | ▼ −6.22% | $89.96 (−19.97%) |
Aug 11, 2026 7w ago | Insider Cluster | $112.41 $103.28 | ▼ −8.12% | ▼ −6.22% | $89.96 (−19.97%) |
Aug 11, 2026 7w ago | Insider Cluster | $112.41 $103.28 | ▼ −8.12% | ▼ −6.22% | $89.96 (−19.97%) |
Aug 11, 2026 7w ago | Insider Cluster | $112.41 $103.28 | ▲ +8.12% | ▲ +6.22% | $89.96 (+19.97%) |
Aug 10, 2026 7w ago | 144 | $108.49 $107.04 | ▼ −1.34% | ▼ −0.28% | $89.96 (−17.08%) |
Jun 29, 2026 13w ago | Press Release | $95.68 $103.87 | ▲ +8.56% | ▲ +8.84% | $89.96 (−5.98%) |
Jun 12, 2026 16w ago | 8-K | $82.07 $97.60 | ▲ +18.92% | ▲ +17.14% | $89.96 (+9.61%) |
Jun 11, 2026 16w ago | Institutional Cluster | $76.45 $100.03 | ▲ +30.84% | ▲ +28.95% | $89.96 (+17.67%) |
May 5, 2026 21w ago | 8-K | $90.42 $84.97 | ▼ −6.03% | ▼ −8.81% | $89.96 (−0.51%) |
Mar 12, 2026 29w ago | Press Release | $77.86 $90.00 | ▲ +15.59% | ▲ +12.00% | $89.96 (+15.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access